ASCO 2023 | SWOG S1826: nivolumab+AVD vs brentuximab vedotin+AVD for advanced stage Hodgkin lymphoma
Neha Mehta-Shah, MD, Washington University in St Louis, St Louis, MO, highlights key findings in the lymphoma field presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress, focusing on SWOG S1826 (NCT03907488), a Phase III trial comparing nivolumab against brentuximab vedotin when given with chemotherapy (AVD) for newly diagnosed, advanced stage Hodgkin lymphoma (HL). The nivolumab-AVD combination led to a higher progression-free survival (PFS) at one year and exhibited significantly lower toxicity compared to brentuximab. This offers a promising alternative therapy for patients with HL. This interview took place at the ASCO 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
